UTM addresses the increasing demand for aptamers in disease treatment with its innovative in silico APTc-19 Aptamer screening method. This approach offers significant cost savings of up to 50% compared to current SELEX testing, making it an attractive option for researchers and laboratories. Positioned to meet the growing demand for technology in combating diseases like COVID-19, Rapid in silico APTc-19 provides user-friendly screening, ensuring accessibility even for inexperienced laboratory personnel. With its cost-effective approach and ease of use, UTM's method stands out as a competitive solution in the field of aptamer development, promising advancements in disease treatment and management.
